N-9 efficacy study
This article was originally published in The Tan Sheet
Executive Summary
Risk of HIV-1 infection was "especially high" in women who used nonoxynol-9 more than 3.5 times per day due to "an increasing frequency of lesions" caused by the spermicide, researchers report in Sept. 28 Lancet. Lut Van Damme, MD, Institute of Tropical Medicine, Antwerp, Belgium, et al., found that at low-frequency use, N-9 had no effect on HIV-1 infection. Researchers randomized 892 sex workers in South Africa, Thailand, Benin and Ivory Coast to either 3.5% N-9 gel or placebo; investigators conclude the drug "no longer has a part to play in HIV-1 prevention"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.